Medicine Recommendations

LSCMMG

Red

BwD

Red

Red

Red

Red

Red

Red

Red

Red

Botulinum Toxin Type A

Date Posted: 01 - May - 2013

BNF chapter: Central nervous system

Expand/Collapse

Chronic migraine (NICE TA260)

NICE TA260 - Botulinum toxin type A for the prevention of headaches in adults with chronic migraine

Red

Red

Red

Red

Red

Red

Red

Red

Red

Botulinum Toxin Type A

Date Posted: 01 - Mar - 2014

BNF chapter: Central nervous system

Expand/Collapse

Contracture of the joint in Multiple Sclerosis

Black

Black

Black

Black

Black

Black

Black

Black

Black

Botulinum Toxin Type A

Date Posted: 01 - Apr - 2018

BNF chapter: Central nervous system

Expand/Collapse

Cosmetic procedures

Red

Red

Red

Red

Red

Red

Red

Red

Red

Botulinum Toxin Type A

Date Posted: 01 - Mar - 2014

BNF chapter: Central nervous system

Expand/Collapse

Focal Spasticity in Multiple Sclerosis

Multiple sclerosis in adults: management (NICE CG186)

NICE Pathway - Spasticity in children and young people overview

Red

Red

Red

Red

Red

Red

Red

Red

Pending

Botulinum Toxin Type A

Date Posted: 01 - Mar - 2014

BNF chapter: Central nervous system

Expand/Collapse

Focal spasticity, Hand and wrist disability associated with stroke, Blepharospasm, Hemifacial spasm, Spasmodic torticollis.

Black

Pending

Black

Black

Pending

Black

Black

Black

Black

Botulinum Toxin Type A

Date Posted: 01 - Mar - 2014

BNF chapter: Central nervous system

Expand/Collapse

Hyperhidrosis due to social anxiety disorder

CG 159 - https://www.nice.org.uk/guidance/cg159

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Brivaracetam

Date Posted: 01 - Oct - 2016

BNF chapter: Central nervous system

Expand/Collapse

Adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult, adolescents and children from 4 years of age with epilepsy

MHRA Drug Safety Update - Antiepileptic drugs: updated advice on switching between different manufacturers’ products

Amber 0

Pending

Amber 0

Amber 0

Pending

Amber 0

Amber 0

Amber 0

Pending

Bromocriptine

Date Posted: 01 - Oct - 2014

BNF chapter: Central nervous system

Expand/Collapse

Parkinson's disease

MHRA Drug Safety Update - Ergot-derived dopamine agonists: risk of fibrotic reactions

LSCMMG

Green (R)(Restricted)

Pending

Pending

Grey

Pending

Amber 0

Grey

Green (R)(Restricted)

WL

Pending

Buprenorphine Patches

Date Posted: 01 - May - 2015

BNF chapter: Central nervous system

Expand/Collapse

Pain, in patients who are unable to take or tolerate oral medicine, (including soluble tablets and liquids).

Black

Pending

Black

Black

Pending

Black

Black

Black

Pending

Buspirone

Date Posted: 01 - May - 2013

BNF chapter: Central nervous system

Expand/Collapse

Anxiety (short term use)

Black

Black

Black

Black

Black

Black

Black

Black

Pending

Butobarbital

Date Posted: 01 - May - 2013

BNF chapter: Central nervous system

Expand/Collapse

Severe intractable insomnia only in patients already taking barbiturates

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Cabergoline

Date Posted: 01 - Nov - 2013

BNF chapter: Central nervous system

Expand/Collapse

Parkinson's disease

MHRA Drug Safety Update - Ergot-derived dopamine agonists: risk of fibrotic reactions

Red

Pending

Pending

Pending

Pending

Pending

Pending

Pending

Pending

Cannabidiol with clobazam

Date Posted: 14 - Jan - 2020

BNF chapter: Central nervous system

Expand/Collapse

Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (NICE TA614)

Red

Pending

Pending

Pending

Pending

Pending

Pending

Pending

Pending

Cannabidiol with clobazam

Date Posted: 14 - Jan - 2020

BNF chapter: Central nervous system

Expand/Collapse

Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (NICE TA615)

Black

Black

Black

Black

Black

Black

Black

Black

Black

Cannabis extract – Delta-9-Tetrahydrocannabinol (THC) 27mg and Cannabidiol (CBD) 25mg (Sativex®) oromucosal spray

Date Posted: 18 - Jan - 2023

BNF chapter: Central nervous system

Expand/Collapse

Refractory neuropathic pain

Red

Pending

Pending

Pending

Pending

Pending

Pending

Pending

Pending

Cannabis-Based Medicinal Products

Date Posted: 20 - Aug - 2020

BNF chapter: Central nervous system

Expand/Collapse

Cannabis-Based Products for the management of intractable paediatric epilepsy

Green

Green

Green

Green

Green

Green

Green

Green

Green

Capsaicin cream

Date Posted: 01 - Dec - 2015

BNF chapter: Central nervous system

Expand/Collapse

Localised neuropathic pain (as per LSCMMG Guidelines)

Green

Pending

Green

Green

Pending

Green

Green

Pending

Pending

Capsaicin cream 0.025%

Date Posted: 01 - Jan - 2016

BNF chapter: Central nervous system

Expand/Collapse

Hand and Knee Osteoarthritis (as per LSCMMG Guidelines)

Green

Green

Green

Green

Green

Green

Green

Green

Green

Carbamazepine

Date Posted: 01 - Dec - 2015

BNF chapter: Central nervous system

Expand/Collapse

Trigeminal Neuralgia (as per LSCMMG Guidelines)

MHRA Drug Safety Update - Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Pending

Carbamazepine (tablets, liquids and suppositories)

Date Posted: 01 - May - 2013

BNF chapter: Central nervous system

Expand/Collapse

Prophylaxis of bipolar disorder unresponsive to lithium

MHRA Drug Safety Update - Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions

Breadcrumb

Medicine Recommendations

Chronic migraine (NICE TA260)

Contracture of the joint in Multiple Sclerosis

Cosmetic procedures

Focal Spasticity in Multiple Sclerosis

Focal spasticity, Hand and wrist disability associated with stroke, Blepharospasm, Hemifacial spasm, Spasmodic torticollis.

Hyperhidrosis due to social anxiety disorder

Adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult, adolescents and children from 4 years of age with epilepsy

Parkinson's disease

Pain, in patients who are unable to take or tolerate oral medicine, (including soluble tablets and liquids).

Anxiety (short term use)

Severe intractable insomnia only in patients already taking barbiturates

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration

Parkinson's disease

Cannabis-Based Products for the management of intractable paediatric epilepsy

Localised neuropathic pain (as per LSCMMG Guidelines)

Hand and Knee Osteoarthritis (as per LSCMMG Guidelines)

Trigeminal Neuralgia (as per LSCMMG Guidelines)

Prophylaxis of bipolar disorder unresponsive to lithium